Literature DB >> 17635531

Mass antibiotic treatment to stop an outbreak of meningococcal disease: a molecular analysis.

L H Katz1, A Zelazny, S Scharf, A Hourvitz, N Asor, Y Arbeli, S Yust-Katz, G Smollan-Fredman, M Gdalevich.   

Abstract

The occurrence of three cases of meningococcal disease among children in a small community, two of whom attended the same day-care centre, prompted a programme of mass antibiotic prophylaxis. Nasopharyngeal and throat swabs were obtained on three occasions from all children registered at the day-care centre. Serogroup B Neisseria meningitidis was isolated from 13 of 61 children before prophylaxis, from three children after 2 weeks, and from 19 children after 3 months. Repetitive extragenic palindromic PCR analysis identified several meningococcal strains before treatment, one of which became predominant after 3 months. Mass antibiotic prophylaxis initially suppressed meningococcal carriage, but the carriage rate subsequently rebounded.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635531     DOI: 10.1111/j.1469-0691.2007.01767.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Cluster of three cases of invasive meningococcal disease in a preschool facility in West Bohemia, the Czech Republic.

Authors:  P Pazdiora; I Morávková; T Bergerová; V Struncová; P Křížová; M Musílek; C Beneš
Journal:  Folia Microbiol (Praha)       Date:  2012-08-11       Impact factor: 2.099

2.  Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease.

Authors:  Michael Bröker; Brian Cooper; Lisa M Detora; Jeffrey J Stoddard
Journal:  Infect Drug Resist       Date:  2011-07-22       Impact factor: 4.003

3.  Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome.

Authors:  Nils Mülling; Hana Rohn; Ulrich Vogel; Heike Claus; Benjamin Wilde; Ute Eisenberger; Andreas Kribben; Oliver Witzke; Anja Gäckler
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.